Arbutus to participate in virtual fireside chat at h.c. wainwright bioconnect 2021 conference

Warminster, pa., jan. 04, 2021 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis b virus (hbv) infection, as well as therapies to treat coronaviruses (including covid-19), today announced that the company will participate in a virtual fireside chat at the h.c. wainwright bioconnect 2021 conference taking place from january 11 – 14, 2021.
ABUS Ratings Summary
ABUS Quant Ranking